Advertisement
Mr Burns has a long and distinguished career in the globalpharmaceuticals industry, having worked for many years for Roche; mostrecently as CEO of their Pharmaceuticals Division and as a member of theRoche Group Corporate Executive Committee. He has extensive experience ofinternational pharmaceuticals and of mergers and acquisitions. Among his manyachievements during his time with Roche, he had significant involvement inthe acquisition and privatisation of Genentech, he led the integration ofBoehringer Mannheim Therapeutics and he played a lead role in thenegotiations resulting in Roche becoming a majority owner of Chugai in Japan.
Advertisement
Mr Burns retired from Roche in January this year. He was appointed on 2March 2010 to be a member of the Board of Directors of Roche Holdings Ltd. MrBurns is also on the Board of Directors of Chugai Pharmaceuticals and ofGenentech Inc.
Says Matthew Emmens, Shire Chairman:
"Bill Burns' global pharmaceutical experience will be invaluable toShire. Shire is growing its business through extending its global reach withestablished operations now in 28 countries and a range of excitinggrowth-driving products with rights around the world."
Says Bill Burns:
"I'm attracted by the approach Shire takes to address specific medicalneeds, and the Company's track record of success and I look forward to makinga contribution to this ambitious and exciting player in the globalpharmaceutical industry."
There is no further information that is required to be disclosed under9.6.13R of the United Kingdom listing rules.
Notes to editors
SHIRE PLC
Shire's strategic goal is to become the leading specialtybiopharmaceutical company that focuses on meeting the needs of the specialistphysician. Shire focuses its business on attention deficit hyperactivitydisorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI)diseases as well as opportunities in other therapeutic areas to the extentthey arise through acquisitions. Shire's in-licensing, merger and acquisitionefforts are focused on products in specialist markets with strongintellectual property protection and global rights. Shire believes that acarefully selected and balanced portfolio of products with strategicallyaligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company's website:http://www.shire.com.
"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORMACT OF 1995
Statements included herein that are not historical facts areforward-looking statements. Such forward-looking statements involve a numberof risks and uncertainties and are subject to change at any time. In theevent such risks or uncertainties materialize, the Company's results could bematerially adversely affected. The risks and uncertainties include, but arenot limited to, risks associated with: the inherent uncertainty of research,development, approval, reimbursement, manufacturing and commercialization ofthe Company's Specialty Pharmaceutical and Human Genetic Therapies products,as well as the ability to secure and integrate new products forcommercialization and/or development; government regulation of the Company'sproducts; the Company's ability to manufacture its products in sufficientquantities to meet demand; the impact of competitive therapies on theCompany's products; the Company's ability to register, maintain and enforcepatents and other intellectual property rights relating to its products; theCompany's ability to obtain and maintain government and other third-partyreimbursement for its products; and other risks and uncertainties detailedfrom time to time in the Company's filings with the Securities and ExchangeCommission.
SOURCE Shire plc
